MedTrace Logo

Clinical Trial for Evaluating the Effectiveness and Safety of Online caIMR in STEMI Patients

NCT06118450 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 335

Last updated 2023-11-08

No results posted yet for this study

Summary

Despite the success of restoration of epicardial blood flow by the primary percutaneous coronary intervention (PPCI), approximately a half of patients with ST-segment elevation myocardial infarction (STEMI) have failed myocardial reperfusion, as reflected by microvascular obstruction (MVO) and intramyocardial haemorrhage (IMH). The coronary angiography-derived index of microvascular resistance (caIMR) is a brand new method for assessing coronary microcirculation in ischemia and no obstructive coronary artery disease (INOCA). In this trial, the investigators aim to verify the safety and effectiveness of caIMR in STEMI who underwent primary PCI. The investigators will immediately measure the caIMR of patients who successfully underwent pPCI, and combine the caIMR with the long-term prognosis, to verify the prognostic performance of caIMR.

Conditions

  • Microvascular Coronary Artery Disease
  • STEMI

Interventions

OTHER

Non-intervention

non-intervention

Sponsors & Collaborators

  • RainMed Medical Group

    collaborator INDUSTRY

  • The Affiliated Hospital of Xuzhou Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2025-02-28
Completion
2025-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06118450 on ClinicalTrials.gov